# | Title | Journal | Year | Citations |
---|
1 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Lancet Oncology, The | 2014 | 3,343 |
2 | Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017 | JAMA Surgery | 2017 | 2,099 |
3 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Lancet Oncology, The | 2016 | 1,866 |
4 | AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 1,802 |
5 | Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents | New England Journal of Medicine | 2014 | 1,645 |
6 | Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases | JAMA - Journal of the American Medical Association | 2016 | 1,225 |
7 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study | Lancet, The | 2020 | 1,224 |
8 | PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project | Journal of Thoracic Oncology | 2017 | 1,067 |
9 | Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma | Journal of Clinical Oncology | 2015 | 778 |
10 | Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention | JAMA - Journal of the American Medical Association | 2016 | 759 |
11 | Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial | Lancet, The | 2016 | 724 |
12 | ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury | American Journal of Gastroenterology | 2014 | 631 |
13 | Guidelines for Perioperative Care in Cardiac Surgery | JAMA Surgery | 2019 | 593 |
14 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study | Lancet Oncology, The | 2020 | 544 |
15 | Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib | JAMA Oncology | 2018 | 522 |
16 | Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial | Lancet, The | 2016 | 512 |
17 | Achieving desired results and improved outcomes: Integrating planning and assessment throughout learning activities | Journal of Continuing Education in the Health Professions | 2009 | 506 |
18 | Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component | Journal of Clinical Oncology | 2017 | 470 |
19 | New Requirements for Resident Duty Hours | JAMA - Journal of the American Medical Association | 2002 | 453 |
20 | Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer | JAMA Oncology | 2020 | 446 |
21 | Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial | Blood | 2020 | 436 |
22 | Guidelines for the management of hiatal hernia | Surgical Endoscopy and Other Interventional Techniques | 2013 | 404 |
23 | Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group | Lancet Oncology, The | 2017 | 394 |
24 | Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study | Journal of Clinical Oncology | 2017 | 384 |
25 | International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease | Blood | 2017 | 381 |
26 | Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial | Lancet Oncology, The | 2017 | 377 |
27 | Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement | Journal of Clinical Oncology | 2017 | 331 |
28 | Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement | Journal of Clinical Oncology | 2015 | 330 |
29 | Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network | Hepatology | 2014 | 326 |
30 | Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations | Biology of Blood and Marrow Transplantation | 2014 | 305 |
31 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study | Lancet, The | 2020 | 299 |
32 | Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer | JAMA Oncology | 2019 | 285 |
33 | 2018 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th Annual Report | Clinical Toxicology | 2019 | 284 |
34 | The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: Part 1—Background, Design Considerations, and Model Development | Annals of Thoracic Surgery | 2018 | 281 |
35 | Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial | Journal of Clinical Oncology | 2019 | 280 |
36 | The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: Part 2—Statistical Methods and Results | Annals of Thoracic Surgery | 2018 | 268 |
37 | Implementing TMB measurement in clinical practice: considerations on assay requirements | ESMO Open | 2019 | 257 |
38 | 2019 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 37th Annual Report | Clinical Toxicology | 2020 | 253 |
39 | B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia | 2020 | 253 |
40 | SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study | Cancer Discovery | 2018 | 244 |
41 | Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction | Journal of the American College of Cardiology | 2015 | 240 |
42 | A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee | Journal of Thoracic Oncology | 2020 | 234 |
43 | International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease | Blood | 2018 | 232 |
44 | Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer | JAMA Oncology | 2020 | 229 |
45 | New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) | Leukemia | 2014 | 214 |
46 | CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance | Frontiers in Immunology | 2018 | 212 |
47 | Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States | Blood | 2017 | 210 |
48 | The current state of molecular testing in the treatment of patients with solid tumors, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 203 |
49 | Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening | JAMA Cardiology | 2021 | 202 |
50 | A Mind-Body Program for Older Adults With Chronic Low Back Pain | JAMA Internal Medicine | 2016 | 200 |